All articles tagged with #obesity
Hong Kong researchers found that brisk interval walking performed once weekly reduces body fat and improves cardiorespiratory fitness in adults with central obesity to a similar extent as exercising three times weekly, offering a time-efficient option for busy individuals.
New EPIC Research trackers using COSMOS data show GLP-1 prescriptions have risen fourfold since 2021, while obesity within the dataset declined from 42% to 41%, with GLP-1 users seeing a bigger drop (75% to 69%). While not nationally representative, the trend aligns with CDC estimates and other surveys that show rising GLP-1 use. Barriers like side effects, cost, and insurance limit adoption (about 12% of Americans), and cheaper generics abroad could arrive in five years. If adoption continues, obesity could decline further, though long-term effects remain uncertain.
A six-month randomized trial with 251 adults who had central obesity found no significant cognitive improvements from eating one avocado daily compared to a control group. Memory, processing speed, and executive function showed no meaningful gains, with any minor improvements likely due to practice effects rather than the avocado. Age did not alter the outcome, suggesting that a single nutrient-dense food is not a quick fix for brain health and that effects may depend on weight status or require broader dietary changes.
Scientists at Helmholtz Munich created a hybrid 'Trojan horse' drug that uses GLP-1R/GIPR signaling as an entry door and carries lanifibranor to activate PPARα/γ/δ inside cells, hitting five targets. In diet-induced obese mice, it reduced appetite, produced greater weight loss, and improved blood glucose versus reference therapies, with GI side effects similar to current incretin medicines. The approach is preclinical; whether results translate to humans remains to be seen and will require clinical development.
A health report suggests that about 50% of cancers that could be prevented are linked to two modifiable lifestyle factors, underscoring the impact of quitting smoking and maintaining a healthy weight in reducing cancer risk.
Eli Lilly's retatrutide, a weekly triple hormone receptor agonist (GLP-1, GIP, glucagon), produced an average 28.3% weight loss (70.3 lb) over 80 weeks at the 12 mg dose in a Phase 3 trial of 2,339 adults with obesity or overweight and a weight-related comorbidity. The 12 mg group lost more weight than the 9 mg and 4 mg groups, with 65.3% reaching a BMI below 30 and 37.5% starting with BMI ≥40; 45.3% achieved at least 30% weight loss. Retatrutide’s weight loss appears to exceed current drugs Wegovy and Zepbound. The drug, which combines GLP-1 and GIP with glucagon, also improved cardio-metabolic risk factors, though side effects such as nausea, diarrhea, constipation, and vomiting increased with dose.
Lilly’s triple-G obesity drug retatrutide met primary endpoints in Phase 3 TRIUMPH-1, delivering up to 28.3% weight loss at 80 weeks for the highest dose on the efficacy estimand (vs 2.2% for placebo). On the treatment-regimen estimand, weight losses were 17.6% (4 mg), 23.7% (9 mg) and 25% (12 mg) with placebo at 3.9%. A Week 104 readout for the top dose reached 29.9% among patients who stayed on therapy. The topline did not include sleep apnea or osteoarthritis pain data. Safety showed higher discontinuations at the high dose (11.3% vs 4.9% placebo) and notable dysesthesia (20.9% at high dose); GI adverse events were more common at the low dose. Analysts said the results meet key endpoints but didn’t exceed expectations, and Lilly is eyeing possible FDA submission this year amid competition from Wegovy and other obesity drugs.
Eli Lilly announced topline TRIUMPH-1 results for retatrutide, a first-in-class GIP/GLP-1/glucagon triple agonist, in adults with obesity or overweight and comorbidities. Across 4 mg, 9 mg, and 12 mg doses, participants achieved meaningful weight loss at 80 weeks (4 mg: 19.0%, 9 mg: 25.9%, 12 mg: 28.3%), with the 12 mg group averaging 70.3 lb and 45.3% reaching ≥30% weight loss; BMI ≤22 was achieved by 65.3% at Week 80. Some participants with higher BMI continued losing weight in extensions, reaching about 30% total body weight loss over roughly two years. All arms met primary and key secondary endpoints, and the follow-on extension data covered up to 104 weeks. Safety disclosures mirror warnings associated with Lilly's obesity medicines.
In the TRIUMPH-1 Phase 3 trial, Lilly’s triple hormone agonist retatrutide produced clinically meaningful weight loss across all dose groups over 80 weeks: 12 mg yielded an average 70.3 lb loss (28.3%) with 45.3% achieving ≥30% weight reduction, and 65.3% reached BMI 22 at Week 80; 9 mg achieved 64.4 lb (25.9%) and 4 mg 47.2 lb (19.0%). An extension up to 104 weeks showed continued weight loss in some participants, including those with higher baseline BMI. The data support retatrutide’s potential as a non-surgical obesity treatment, with detailed safety labeling included in the release.
Lilly reports that retatrutide, a triple agonist of GLP-1, GIP, and glucagon, produced up to about 85 pounds (roughly 30% of body weight) loss in a phase 3 trial of ~2,300 people with obesity or overweight, with the highest weekly dose averaging 28% weight loss over 80 weeks (some participants continued to 104 weeks). If approved, it could surpass current GLP-1 meds and aid patients who don’t respond to those drugs. Side effects include nausea, GI issues, skin sensations, and UTIs. Full results haven’t been published in a medical journal, and an FDA filing could occur as early as this year.
Phase 3 data show Lilly’s investigational triple-hormone drug retatrutide delivering up to 28.3% average weight loss over 80 weeks at the highest dose (vs. 2.2% placebo), with about 45% of patients achieving 30%+ loss and even greater reductions in those with BMI ≥35. A lower 4 mg dose yielded 19% weight loss with better tolerability. Common side effects were GI (nausea, diarrhea, constipation); no major cardiac or liver issues were observed. If results hold, Lilly could file for approval, potentially solidifying retatrutide as a top player in a booming obesity market, ahead of Novo Nordisk’s competing therapies.
In a mouse study, obese mice on a high-fat, high-sugar diet treated with THC lost weight and body fat, but only those given a full-plant cannabis extract showed improved glucose tolerance; THC alone did not yield this metabolic benefit, suggesting other cannabis compounds drive the positive effects. The work, published in The Journal of Physiology, cautions against drawing human conclusions and highlights the need for further research into non-THC cannabinoids like CBG and other plant compounds.
A new AI suite called MouseMapper uses foundation-model–based 3D imaging to automatically segment nerves, immune cells, and 31 organs across an entire mouse body, enabling multi-system analyses of obesity. Built on VesselFM, it comprises a Nerve-Module, Immune-Module, and Tissue-Module that generalize across imaging resolutions and labeling strategies. In diet-induced obesity, the framework reveals reduced whole-body nerve density, increased nerve presence in adipose tissue, and notable infraorbital nerve remodeling in the trigeminal nerve linked to sensory deficits. Spatial proteomics of the trigeminal ganglion shows actin cytoskeleton and inflammation pathway changes, conserved in obese humans. Additionally, MouseMapper generates whole-body inflammation maps by profiling Cd68+ immune-cell clusters across tissues, illustrating systemic, organ-wide perturbations and offering a scalable bridge from cell-level changes to whole-body disease phenotypes.
Orforglipron, a once-daily small-molecule pill that targets the GLP-1 system and has FDA approval for obesity, may help people keep most of their weight loss after stopping injections like Wegovy or Mounjaro. In a randomized trial, those who switched to orforglipron regained about 26% of lost weight (vs over 50% on placebo) after 52 weeks, with more than two-fifths maintaining at least 80% of their weight loss and improved health markers such as blood sugar, blood pressure, insulin and cholesterol. The pill could be cheaper and easier to store than peptide injections, but it is not yet licensed in the UK for weight loss, and US monthly costs are roughly $149–$299.
Orforglipron, a once-daily pill-based GLP-1 weight‑loss drug, could sustain weight loss and cut costs versus injections like Wegovy and Mounjaro. In a small trial, switching to orforglipron after initial weight loss reduced weight regain markedly (about 26% with orforglipron vs 50%+ on placebo for Mounjaro; about 21% vs 62% for Wegovy) while preserving health benefits; US monthly price is roughly $149–$299 vs over $1,000 for Mounjaro, and the UK has not yet licensed it but expects approval around late 2026–early 2027.